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httcense.Abstract Background: Omalizumab is a monoclonal anti-immunoglobulin E (IgE) antibody indi-
cated for the treatment of inadequately controlled severe persistent asthma despite optimal control-
ler therapy. It is an expensive medication so there is a need to identify those patients most likely to
beneﬁt.
Aim of the study: To investigate characteristics associated with response to omalizumab in dif-
ﬁcult asthma.
Patients and methods: The study enrolled 42 patients (15 female, 27 male) with age range (20 y–
52 y) with severe asthma that was inadequately controlled despite step 4 treatment as described in
(GINA) guidelines. Omalizumab was given as add-on therapy to concomitant asthma treatment
and administered subcutaneously every 2 or 4 weeks according to patients’ pretreatment body-
weight and baseline IgE levels, for at least 16 weeks. Those who showed better asthma control were
analyzed to investigate whether pre-treatment patient baseline clinical characteristics could be reli-
ably identiﬁed and to be predictive of a superior response to omalizumab.
Results: {(12/42 (28.6%)} of enrolled patients showed better asthma control. Using univariate
and multivariate regression analysis, many variables showed signiﬁcant effect on response to oma-
lizumab including; age, duration of asthma, history of allergic rhinitis, history of allergic dermatitis,
bronchial reversibility, no of positive results to common allergen in immediate skin-prick test, spu-
tum eosinophilia and baseline total (IgE).w; OCS, oral corticosteroids;
RCH, Royal Commission
90094748.
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16 N.M. AbdelatyConclusion: Omalizumab is an expensive medication so it is recommended to target its use to
patients most likely to beneﬁt rather than recommend widespread use. Further studies are needed
to conﬁrm these data
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IgE is central to the pathophysiology of allergic asthma and re-
lated conditions such as allergic rhinitis, providing a strong
rationale for the development of anti-IgE therapy for the treat-
ment of these diseases [1].
Omalizumab is a recombinant humanized monoclonal anti-
body IgG1 that selectively binds to human immunoglobulin E
(IgE). It is constructed from the constant region of IgG1 k hu-
man framework with a variable sequence of mouse antibody.
It is >95% human IgG and <5% mouse antibody [2]. By
binding to free IgE, omalizumab reduces the level of circulat-
ing free IgE by up to 99%, prevents IgE from attaching to
mast cells and basophiles, down-regulates FceRI expression,
and attenuates the inﬂammatory response to allergens [3].
The current indication for omalizumab is the management of
adult and adolescent patients with moderate to severe allergic
asthma, who are already being treated with inhaled steroids,
and who have serum IgE levels corresponding to the recom-
mended dose range (>30 to 700 IU/ml) [4].
Treatment with omalizumab attenuates early and late phase
responses to inhaled allergen challenge. There is accumulating
evidence to show that omalizumab reduces the activity of a
variety of pro-inﬂammatory cells (including eosinophils, mast
cells and basophils) and down-regulates release of pro-inﬂam-
matory mediators, thereby attenuating both the acute and
chronic phases of allergic inﬂammation. In addition, the effects
of omalizumab on antigen-presenting cells (dendritic cells)
indicate that it may also block the sensitization phase, as well
as the effector phase [5].
Clinical studies in patients with asthma have shown that
omalizumab reduces asthma exacerbations, severe asthma
exacerbations, inhaled corticosteroid requirements, and emer-
gency visits, as well as signiﬁcantly improving asthma-related
quality of life, morning PEF and asthma symptom scores in
patients with severe allergic (IgE-mediated) asthma in addition
to considerable reduction in the need for maintenance OCS,
especially in patients with severe asthma and whose asthma
is inadequately controlled despite Global Initiative for Asthma
(GINA) step 4 therapy, usually termed difﬁcult-to-treat
asthma.
Omalizumab is an expensive medication, the actual costs
are relative to the dose required, but range from about AU$
7800 to 50,000 per annum. Moreover, although the safety pro-
ﬁle of omalizumab, as available from early controlled studies
and post-marketing experience, appears favorable, the occur-
rence of anaphylactic reactions and concerns regarding the
possibility of increased rates of malignancy should lead to cau-
tionary measures in obtaining consent and managing subjects.
Thus, in addition to strict criteria for selection, the most
important of which are to conﬁrm the diagnosis of asthma,
to exclude masquerading conditions and to ensure that optimal
conventional therapy has been tried, there is also a need toidentify individual responders to this drug, rather than recom-
mend widespread use in difﬁcult asthma [1–5].
The aim of the present exploratory analysis was to deter-
mine baseline patient characteristics that could be predictive
of the best response to omalizumab therapy for allergic
asthma.
Methods Study Patients
The study was prospective, open label, recruiting patients
through the chest outpatient clinic in RCH, Jubail, KSA.
The study enrolled patients with a diagnosis of severe persis-
tent allergic asthma that was inadequately controlled (at least
6 months prior to enrolling in the study) despite step 4 treat-
ment as described in the GINA 2002 guidelines [6]. Patients
deemed eligible for omalizumab treatment have had their exist-
ing standard treatments optimized as well as having behavioral
and psychosocial issues addressed 6 month before starting
omalizumab.
Beginning in Jan 2009 till December 2011, we enrolled 42
patient with serum total IgE level of 30 to 700 IU/mL, and a
had positive, immediate skin-prick test result to at least one
common allergen (dust mite, dog or cat or cockroach).
The inclusion criteria for enrollment included adult and
adolescent patients (12 years and older) with severe persistent
allergic asthma who have a positive skin test to a perennial
aeroallergen and who have reduced lung function (forced expi-
ratory volume in 1 s, FEV1 < 80%) as well as frequent day-
time symptoms or night-time awakenings and who have had
multiple documented severe asthma exacerbations despite dai-
ly high-dose inhaled corticosteroids, plus a long-acting inhaled
beta-2 agonist.
Exclusion criteria: (1) smoking status, (2) unconﬁrmed
diagnosis of asthma, (3) comorbidities including COPD,
chronic sinusitis, gastroesophageal reﬂux, obesity, obstructive
sleep apnea, psychological and psychiatric disorders.
Study protocol
Baseline data was collected and included age, sex, duration of
asthma, symptoms of asthma, daytime symptoms, limitation
of activities, nocturnal symptoms/awakening, usage of rescue
bronchodilators, lung function (FEV1), bronchial reversibility,
current asthma treatment, history of receiving OCS, skin-prick
test result to common allergen, history of allergic rhinitis and/
or allergic dermatitis, sputum eosinophilia (P3%), and base-
line total (IgE), in addition to number of asthma exacerbation
within the year prior to enrolling in the study.
Omalizumab was given as add-on therapy to standard asth-
ma therapy which included inhaled corticosteroids (ICS), long-
acting beta-2 agonists, short-acting beta-2 agonists, oral corti-
costeroids (OCS), leukotriene antagonists and where appropri-
ate, theophylline. Omalizumab is available as a powder for
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2 or 4 weeks according to patients’ pretreatment bodyweight
and baseline IgE levels using a dosing table for at least 16
weeks. The population cohort was assessed at 16 weeks for re-
sponse to omalizumab treatment.
Throughout the study, patients recorded symptoms of asth-
ma, daytime symptoms, limitation of activities, nocturnal
symptoms/awakening, usage of rescue bronchodilators in daily
diary cards.
Each patient was assessed to establish his or her current
treatment regimen, adherence to the current regimen, and level
of asthma control during monthly clinic visits using GINA
guidelines’ simpliﬁed scheme for recognizing controlled, partly
controlled, and uncontrolled asthma [6]. If control has been
maintained for three months, treatment can be stepped down
with the aim of establishing the lowest step and dose of treat-
ment that maintains control. If asthma is partly controlled, an
increase in treatment should be considered.
Outcome measures
Degree of asthma control; success in initiating oral corticoste-
roids withdrawal; or step down of high dose ICS; control of
exacerbations; the number of clinically signiﬁcant asthma
exacerbations during the treatment phase, avoidance of
unscheduled healthcare utilization; spirometry measures and
a global evaluation of treatment effectiveness, as assessed by
the physician. An exacerbation was deﬁned as worsening of
asthma symptoms severe enough to require systemic steroids
or a doubling of the patients’ baseline ICS dose [7].
Identifying patients who respond to omalizumab therapy
Overall asthma control [6] is especially relevant in severe asth-
ma as it takes into account many aspects of clinical disease.
Those who showed improvement in degree of asthma con-
trol using GINA guidelines’ scheme [6] were labeled as Good
Responders to omalizumab, with assessment of success in ini-
tiating oral corticosteroids withdrawal; success in step down of
high dose ICS; or other asthma treatment, less need of rescue
medication, less daytime symptoms, less nocturnal symptoms,
better control of exacerbations, less ER visits, improvement in
FEV1 and physician’s overall assessment.
Statistical analysis
Data entry and analysis
After the data were collected, they were coded and transferred
directly into the computer. The Statistical Package for Social
Science (SPSS) was used. The following descriptive measures
were used: count, percent, arithmetic mean and standard devi-
ation. Correlation matrix was done to study the relation be-
tween two or more quantitative variables. The least
signiﬁcant level was at P< 0.05.
Ability of pre-treatment baseline measures to predict response to
omalizumab
Univariate and multivariate analysis were performed where the
response to omalizumab was the dependent variable and thefollowing baseline variables were included in the model as
independent variables: age, sex, duration of asthma, degree
of asthma control, lung function (FEV1), bronchial reversibil-
ity, history of receiving OCS, no of positive results in skin-
prick test to common allergen, history of allergic rhinitis, aller-
gic dermatitis, sputum eosinophilia, and baseline total (IgE), in
addition to number of asthma exacerbation within the year
prior to enrolling in the study.Results
Patient population comprised 42 adults (15 female, 27 male),
with age range (20 y–52 y), with severe asthma that was inad-
equately controlled despite step 4 treatment as described in
(GINA) guidelines and who were eligible for omalizumab
treatment for at least 16 weeks.
Baseline characteristics of patient population are showed in
(Table 1); Patient had asthma duration range from {14– 32
with (mean ± SD) 20.0 ± 5.0}. 9.5% of patient had predni-
sone-dependent asthma; 66.6% had concomitant allergic rhini-
tis, 11.9% had concomitant allergic dermatitis; and 14.3%
showed sputum eosinophilia (P3%). Baseline IgE range from
{80730 (mean ± SD) 500 ± 83} IU/mL; base line usage of
rescue bronchodilators (puff/day) showed mean of 5.2 ± 3.0,
baseline bronchial reversibility range from {(12–25%)
(mean ± SD) 18 ± 4.8} and baseline FEV1 range from {44–
75 (mean ± SD) 62.7 ± 10.8}.Identifying patients who respond to omalizumab therapy
Before starting omalizumab, 25 patient out of 42 (59.5%) were
in the category of uncontrolled asthma and 17/42 (40.5%)
were in the category of partly controlled asthma, no one in
our cohort was in the controlled category. Based on deﬁnition
of response, as improvement in degree of asthma control
according to GINA guidelines (Table 2), with no asthma exac-
erbation during 16 weeks of treatment, 12 patients of our co-
hort (28.6%) showed response omalizumab and were labeled
as responders (Table 3).
On comparing baseline characteristics of patients in oma-
lizumab responder and non-responder groups, there was no
statistical signiﬁcant difference in gender, usage of rescue bron-
chodilators, FEV1,%, history of receiving OCS, and number of
asthma exacerbation within the year prior to enrolling in the
study. Responder group showed signiﬁcantly higher bronchial
reversibility, higher baseline IgE, and higher no. of positive
allergens. Also responder group showed higher rates of allergic
rhinitis, allergic dermatitis, and sputum eosinophilia. Respon-
der group had Less duration of asthma, and younger age
(Table 4).
Correlation coefﬁcients between baseline characteristics of
patients and response to omalizumab is shown in (Table 5).
In the univariate analysis, age, duration of asthma, history
of allergic Rhinitis, history of allergic dermatitis, bronchial
reversibility, no of positive results to common allergen in
immediate skin-prick, sputum eosinophilia and baseline total
(IgE) had an interaction with response to omalizumab, with
predictive value of improvement in asthma control, whereas
inconsistent results were obtained for gender, usage of rescue
bronchodilators, FEV1,%, history of receiving OCS, and num-
Table 1 Baseline characteristics of patients in the cohort (n= 42).
Characteristicsa Range Mean ± SD
Male/female gender, No. 27/15
Age, yr 20–52 35.5 ± 8.2
Duration of asthma years 14–32 20.0 ± 5.0
Usage of rescue bronchodilators puﬀ/day 02–10 5.0 ± 3.0
FEV1,% predicted 44–75 62.7 ± 10.8
Bronchial reversibility% 12–25 18 ± 4.8
Baseline total (IgE) IU/mL 80–730 500 ± 83
Skin-prick test result to common allergen 1–9 4.0 ± 2.1
Number of asthma exacerbation within the year prior to enrolling in the study 1–4 2.0 ± 1.0
Patients (N= 42)
No. %
History of receiving OCS, Y/n 04/42 9.5
History of allergic rhinitis, Y/n 28/42 66.6
History of allergic dermatitis, Y/n 05/42 11.9
Sputum eosinophilia, Y/n 06/42 14.3
a Data are presented as range, mean (SD) unless otherwise indicated. OCS: oral corticosteroids.
Table 2 Response rates (after 16 weeks of treatment), according to deﬁnition of response.
Levels asthma
control of
Before starting
omalizumab no. (%)
16 weeks after
omalizumab no. (%)
Controlled 0 5 (11.9)
Partly controlled 17 (40.5) 3 controlled 
2 uncontrolled
12 no change (partly controlled)
19 (45)
Uncontrolled 25 (59.5) 2 controlled 
7 partly controlled 
16 no change (uncontrolled)
18 (43)
; responder to omalizumab
Table 3 Levels of asthma control.
Characteristic Controlled (all of
the following)
Partly controlled (any present
in any week)
Uncontrolled
Daytime symptoms Twice or less per
week
More than twice per week 3 or more features of partly
controlled asthma present in any
week
Limitations of
activities
None Any
Nocturnal symptoms
/ awakening
None Any
Need for rescue /
‘‘reliever’’ treatment
Twice or less per
week
More than twice per week
Lung function (PEF
or FEV1)
Normal <80% predicted or personal
best (if known) on any day
Quoted from Global strategy for asthma management and prevention (updated 2010): global Initiative for Asthma (GINA). http://
www.ginasthma.org; 2010.
18 N.M. Abdelatyber of asthma exacerbation within the year prior to enrolling in
the study.
Using the multivariate regression analysis, a signiﬁcant
effect of allergic rhinitis, sputum eosinophilia and no ofpositive allergens on treatment response was consistent
(95% [CI], 0.25 to 0.38; p< 0.000), (95% CI, 0.13 to
0.15; p< 0.000), and (95% CI, 0.12 to 0.09), respectively
(Table 6).
Table 4 Comparison Of baseline characteristics of patients in the responder and non-responder to omalizumab.
Characteristics Responder no (%) 12/42 (28.6) Non-responder No (%) 30/42 (71.4) p
Male/female gender, No. 05 / 12 12 / 30 NS
Age, yr, mean (SD) 27 ± 6.3 32.5 ± 5.8 < 0.05
Duration of asthma years mean (SD) 17.0 ± 2.1 22.0 ± 7.0 < 0.1
Usage of rescue bronchodilators puﬀ/day mean (SD) 6.0 ± 2.2 5.0 ± 3.0 NS
FEV1, % predicted mean (SD) 60 ± 10.0 62.7 ± 10.8 NS
Bronchial reversibility % mean (SD) 20.0 ± 3.1 17.0 ± 3.5 < 0.05
Baseline total (IgE) IU/mL mean (SD) 400 ± 150 320 ± 100 < 0.001
Skin-prick test result to common allergen mean (SD) 4.2 ± 3.0 2.0 ± 1.0 < 0.01
Number of asthma exacerbation within the year prior to
enrolling in the study, mean (SD)
2.5 ± 1.1 2.1 ± 1.0 NS
History of receiving OCS, No (%) 1/12 3/30 NS
History of allergic rhinitis, No (%) 10/12 18/30 < 0.001
History of allergic dermatitis, No (%) 2/12 3/30 < 0.05
Sputum eosinophilia, No (%) 04/12 2/30 <0.05
Data are presented as mean (SD) unless otherwise indicated. OCS: oral corticosteroids.
Table 5 Correlation coefﬁcients between baseline characteristics of patients and responding to omalizumab (degree of asthma
control).
Variable R P Sig.
Male/female gender, No. 0.082 0.364 NS
Age, yr, mean (SD) 0.79 0.000 HS
Duration of asthma years mean (SD) 0.06 0.050 S
Usage of rescue bronchodilators puﬀ / day mean (SD) 0.153 0.087 NS
FEV1, % predicted mean (SD) 0.028 0.759 NS
Bronchial reversibility % mean (SD) 0.82 0.000 HS
Baseline total (IgE) IU/mL mean (SD) 0.769 0.000 HS
Skin-prick test result to common allergen mean (SD) 0.82 0.000 HS
Number of asthma exacerbation within the year prior to enrolling in the study, mean (SD) 0.027 0.766 NS
History of receiving OCS, No (%) 0.12 0.17 NS
History of allergic rhinitis, No (%) 0.527 0.000 HS
History of allergic dermatitis, No (%) 0.195 0.029 S
Sputum eosinophilia, No (%) 0.174 0.05 S
Data are presented as mean (SD) unless otherwise indicated. OCS: oral corticosteroids.
Table 6 Predicting-responder to omalizumab various
variables.
Variable Beta t-Value P-value 95%CI
Allergic rhinitis 4.74 0.312 0.000 0.25 to 0.38
Sputum eosinophilia 3.21 0.211 0.000 0.13 to 0.15
No of positive allergen 2.10 0.125 0.001 0.12 to 0.09
Adjusted r2 = 0.62, all these variables could predict 62% of num-
ber of hospitalization. Signiﬁcance at 0.05, HS at 0.01.
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Omalizumab is an expensive medication and, it is important to
recognize that not all patients respond to omalizumab treat-
ment. Identiﬁcation of those patients most likely to achieve
the greatest beneﬁt from omalizumab therapy will minimizeunwarranted drug exposure and healthcare expenditure. Oma-
lizumab treatment should only be initiated after a comprehen-
sive and exhaustive assessment including establishment of
correct diagnosis and compliance with standard optimized
treatments especially ICS [8].
It is recommended that the physician’s overall assessment
should be used to identify responders after 16 weeks of ther-
apy, thus targeting the treatment to the patients most likely
to beneﬁt. When treatment is directed at these responders,
omalizumab has been shown to provide cost effective therapy
for inadequately controlled severe persistent allergic (IgE-med-
iated) asthma [1].
Predicting response to omalizumab in patients with inade-
quately controlled severe persistent allergic asthma is of great
clinical relevance. Careful clinical assessment of response is re-
quired using validated tools. In the present study, based on
GINA guidelines, we used the improvement in degree of asth-
ma control as indicator of response to omalizumab and to
characterize baseline features of such patients.
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able, it appears that the greatest beneﬁt from add-on oma-
lizumab therapy is observed for the subgroup of more
difﬁcult-to-treat patients [9].
In the present study, it is worth noting that, 12 patients of
our cohort showed response to omalizumab (Response rate
28.6%). We deﬁned response by strict criteria of GINA guide-
lines, which is the improvement in degree of asthma control
with no asthma exacerbation during 16 weeks of treatment.
Before starting omalizumab, all our patients were considered
to have severe asthma as 25 patient out of 42 (59.5%) were
in the category of uncontrolled asthma and 17/42 (40.5%)
were in the category of partly controlled asthma, despite opti-
mized treatment for at least 6m before commencing the study.
In this respect, Bousquet et al. [9] have analyzed data from
several trials to examine predictors of response to omalizumab
as add on therapy in severe asthma. They found that the re-
sponse rate was 65% at 16 weeks and a minimum trial of 12
weeks was recommended. Response rate in the current study
is much less (28.6%). This difference is mostly because we used
more strict measure of response, that is improvement in degree
of control of asthma as deﬁned by GINA guidelines. Whereas,
Bousquet et al. [9] deﬁned response by a composite measure of
one of four criteria with no asthma exacerbation over 16 weeks
therapy; these criteria are; reduced symptoms P1 mean total
asthma score with no increase in beta 2 agonist use; reduction
P1 mean number of puffs rescue medication/day with no in-
crease in total symptom score; mean increase in PEF P15%;
increase overall scoreP1 Juniper Asthma QOL questionnaire.
In a subsequent large study by Bousquet et al. [7], physi-
cian’s overall assessment of treatment was found to be the
most reliable tool to identify patients who respond to oma-
lizumab and no one item appearing more reliable than global
assessment. They concluded that this simple measurement can
be used to determine whether treatment should continue
beyond an initial 16-week trial of omalizumab therapy. Impor-
tantly, lung function improvement only identiﬁed approxi-
mately half of those who ‘‘responded’’ to omalizumab. These
data strengthen our choice of improvement in degree of
control of asthma deﬁned by GINA guidelines as a measure
of response to omalizumab.
The predictors of response in Bousquet et al. [9] study, in-
cluded a history of ED treatment in the last 12 months, high
dose of inhaled BDP and low FEV1, while in our study respon-
der group showed signiﬁcantly higher bronchial reversibility,
higher baseline IgE, and higher no. of positive allergens in skin
prick test. Also responder group showed higher rates of aller-
gic rhinitis, allergic dermatitis, and sputum eosinophilia and
had less duration of asthma, and younger age.
Bousquet and colleagues [10], presented large study with
pooled data from seven studies; ﬁve blinded placebo-con-
trolled plus inhaled corticosteroid, and two open label against
current asthma treatment. The studies attempted to identify a
group of patients in whom the efﬁcacy of omalizumab was
most clearly established by observing exacerbation rates in
subgroups of the pooled dataset. They reported that most of
the patients were in the severe persistent category of asthma
severity by GINA guidelines and overall, the hospital admis-
sions were reduced by 52%, emergency room visits by 61%,
unscheduled doctor visits by 47% and a 47% reduction in
exacerbations for the omalizumab group. But they reported
that it is difﬁcult to predict which patients will gain most ben-eﬁt from treatment with omalizumab based on pre -treatment
baseline characteristics as none of the studied variables (age,
sex, FEV1 and IgE levels) could predict those who responded
to omalizumab.
In contrary to Bousquet et al. study, we observed in our
analysis that age, duration of asthma, history of allergic rhini-
tis, history of allergic dermatitis, bronchial reversibility, no of
positive results to common allergen in immediate skin-prick,
sputum eosinophilia and baseline total (IgE) had an interac-
tion with response to omalizumab, with predictive value of
improvement in asthma control. On the other hand, other vari-
ables did not show correlation with response to omalizumab
including gender, usage of rescue bronchodilators, FEV1%,
history of receiving OCS, and number of asthma exacerbation
within the year prior to enrolling in the study, Using the mul-
tivariate regression analysis, a signiﬁcant effect of allergic rhi-
nitis, sputum eosinophilia and no of positive allergens were
found to be consistent predictor of treatment response (95%
[CI], 0.25 to 0.38; p< 0.000), (95% CI, 0.13 to 0.15;
p< 0.000), and (95% CI, 0.12 to 0.09), respectively.
In this respect, our observations have been conﬁrmed by
many studies. In the INNOVATE study [8], baseline total
IgE was the only consistent predictor of response to emerge
from the univariate and multivariate analyses. However,
pooled analysis of baseline total IgE levels across clinically
important response measures did not consistently support this.
Allergic asthma and allergic rhinitis frequently co-exist, and
are often considered to be components of a single IgE-medi-
ated inﬂammatory condition [11]. Several trials of omalizumab
have been conducted in patients with allergic rhinitis [12]. SO-
LAR study [13], evaluated omalizumab in patients with con-
comitant asthma and perennial allergic rhinitis (PAR), and
showed that in addition to reducing asthma exacerbations,
omalizumab also improved asthma and rhinitis scores on qual-
ity of life scales and led to signiﬁcant improvements in rhinitis
symptoms. Same results were found in other two studies in pa-
tients with seasonal allergic rhinitis (SAR) [14] and one in pa-
tients with (PAR) [15]. In all three studies, omalizumab
signiﬁcantly reduced symptom severity and rescue antihista-
mine use, as well as signiﬁcantly improving rhinitis or rhino-
conjunctivitis-related quality of life in SAR.
In the same context, several small studies and case reports
have been published which indicate a potential beneﬁt of oma-
lizumab therapy in patients with urticaria. In one small study
in patients with chronic autoimmune urticaria, 12 to 16 weeks
following initiation of omalizumab, Urticaria Activity Score
and rescue medication use were signiﬁcantly decreased, and
quality of life was improved [1].
The above studies and our results suggest that omalizumab
may provide additional beneﬁt to omalizumab-treated asthma
patients who also suffer with allergic rhinitis and/or allergic
dermatitis. This may indicate that the more the atopic state
the more the possibility of good response to omalizumab.
Omalizumab has been shown to bring about substantial
reductions in the activity of IgE, eosinophils, basophils, mast
cells, and dendritic cells, resulting in attenuation of the acute
and chronic effector phases of allergic inﬂammation.[5]
A pooled analysis found that omalizumab reduced mean
peripheral blood eosinophil counts, in patients with moderate
to-severe persistent asthma [14,16]. Omalizumab has also been
shown to reduce sputum and bronchial eosinophilia in a study
of 45 patients with mild-to-moderate persistent asthma and
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mean percentage sputum eosinophil counts were signiﬁcantly
greater in omalizumab-treated patients (from 4.8% at baseline
to 0.6% at Week 16) than in placebo recipients (from 5.8% to
2.3%). Eosinophil counts in the bronchial submucosa also de-
creased from80 cells/mm2 at baseline to 1.5 cells/mm2 at
Week 16 in the omalizumab group, but were almost un-
changed in the placebo group.
These ﬁndings have been conﬁrmed in a study in 25 patients
with mild allergic asthma [18]. The median sputum percentage
eosinophil count was reduced from 4.0% at baseline to 0.5%
at 12 weeks in omalizumab-treated patients, compared with
an increase from 2.2% to 2.6% in the placebo group. There
was also a signiﬁcant reduction in median activated eosinophil
counts in biopsies in the omalizumab group (from 15.0 to 0.2
cells/0.1 mm2), with little change in the placebo group)from
14.5 to 11.0 cells/0.1 mm2.
Additionally, omalizumab-treated patients had signiﬁcant
reductions in submucosal IgE+ cells, and CD4+ T-lympho-
cytes. Taken together, these ﬁndings indicate that reductions
in asthma exacerbations brought about by omalizumab may
be mediated through attenuation of airway eosinophilia, while
the reductions in IL-4+ cells may be important in light of the
documented association between persistent IL-4 production
and severe or corticosteroid-resistant asthma [19]. Moreover
all the above data can explain our ﬁnding of correlation be-
tween sputum eosinophilia and response to omalizumab and
support the role of sputum eosinophilia as predictor of oma-
lizumab response.
Although history of receiving OCS did not show correla-
tion with response to omalizumab, effect of omalizumab on
need for systemic corticosteroid treatment has been conﬁrmed
in many studies. Busse and co-workers [20] have studied the ef-
fect of omalizumab on the need for rescue treatment with cor-
ticosteroids. The rate of courses of systemic corticosteroids
was reduced in omalizumab-treated patients relative to control
with an OR of 0.57 (0.48–0.66). This reduction closely corre-
lated with both physician and patient global assessments.
Treatment with omalizumab allowed a signiﬁcant reduction
in concomitant ICS dosage and had oral steroid-sparing bene-
ﬁts for patients [4].
IgE continues to contribute to disease pathogenesis in ato-
pic subjects who have persistent asthma despite treatment with
ICS. In-vitro studies [21] show that corticosteroids enhance,
rather than diminish, IgE production by a direct action on B
cells. Thus, while having the ability to suppress T-helper type
2 cytokine production, a downside of repeated high-dose ICS
treatment could be the maintenance of an ongoing local IgE
response that could be amenable to omalizumab therapy. We
understood that omalizumab can provide steroid-sparing ben-
eﬁts for patients on oral steroids but small no of patients on
oral steroids in our study did not allow to investigate this
theory.
We found that factors indicating more severe asthma
including FEV1%, usage of rescue bronchodilators, and num-
ber of asthma exacerbation within the year prior to enrolling in
the study were not correlated with response to omalizumab,
this raise the probability that the response to omalizumab
was relatively independent of disease severity.
Also the negative correlation of both duration of asthma
and age with the response to omalizumab indicate that oma-
lizumab may be less effective in severe chronic stages of asthmawith well established irreversible changes of airways remodel-
ing, so it may be wise to start omalizumab early, however this
theory need to be conﬁrmed by more studies.Conclusion
As highlighted above, the present study showed that it is pos-
sible to reliably predict which patients will derive the greatest
beneﬁt from omalizumab therapy based on pre-treatment
baseline characteristics. Overall, Asthma patients who beneﬁt
most from add-on treatment with omalizumab are those with
shorter duration of asthma, younger age, history of allergic
rhinitis or allergic dermatitis, more positive results to common
allergen in immediate skin-prick, sputum eosinophilia, bron-
chial reversibility or higher baseline total (IgE). A potential
criticism of our study, is the small number of our cohort but
the fact that the results are so consistent and hang together
clinically as well as statistically, encourages us to believe that
they are reliable and replicable. Taken together, these ﬁndings
will aid the clinical decision of whether a patient is likely to
beneﬁt from receiving omalizumab in addition to standard
therapy for allergic asthma. Ongoing studies continue to eval-
uate the treatment beneﬁts of omalizumab and guide therapy.
Further studies are needed to investigate the potential predic-
tive value of other biomarkers including baseline levels of spe-
ciﬁc IgE, the potential for disease-modiﬁcation in asthma by
use of omalizumab, as is the use of omalizumab in other
IgE-mediated conditions.References
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